Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
24.02
Dollar change
+0.02
Percentage change
0.08
%
IndexRUT P/E9.47 EPS (ttm)2.54 Insider Own1.45% Shs Outstand166.98M Perf Week-0.54%
Market Cap4.06B Forward P/E9.22 EPS next Y2.61 Insider Trans-0.63% Shs Float166.77M Perf Month-1.72%
Income434.43M PEG0.38 EPS next Q0.67 Inst Own105.28% Short Float7.76% Perf Quarter-20.04%
Sales1.73B P/S2.35 EPS this Y90.93% Inst Trans-1.26% Short Ratio6.95 Perf Half Y-1.48%
Book/sh7.42 P/B3.24 EPS next Y-5.21% ROA23.94% Short Interest12.94M Perf Year-11.96%
Cash/sh4.40 P/C5.46 EPS next 5Y24.80% ROE42.85% 52W Range20.46 - 32.88 Perf YTD-13.41%
Dividend Est.- P/FCF10.31 EPS past 5Y- ROI26.88% 52W High-26.95% Beta0.48
Dividend TTM- Quick Ratio2.77 Sales past 5Y10.61% Gross Margin83.32% 52W Low17.40% ATR (14)0.63
Dividend Ex-Date- Current Ratio3.20 EPS Y/Y TTM361.04% Oper. Margin22.07% RSI (14)42.60 Volatility1.90% 2.50%
Employees2100 Debt/Eq0.29 Sales Y/Y TTM54.01% Profit Margin25.17% Recom2.25 Target Price34.67
Option/ShortYes / Yes LT Debt/Eq0.29 EPS Q/Q183.98% Payout0.00% Rel Volume1.00 Prev Close24.00
Sales Surprise-2.74% EPS Surprise-26.21% Sales Q/Q21.83% EarningsMay 01 BMO Avg Volume1.86M Price24.02
SMA20-1.15% SMA50-5.18% SMA200-8.77% Trades Volume1,868,833 Change0.08%
Date Action Analyst Rating Change Price Target Change
Mar-19-24Initiated Robert W. Baird Outperform $37
Feb-20-24Downgrade UBS Neutral → Sell $25
Nov-20-23Resumed JP Morgan Neutral $33
Oct-24-23Upgrade Evercore ISI In-line → Outperform
Oct-17-23Initiated UBS Neutral $31
Nov-03-22Upgrade Piper Sandler Neutral → Overweight $26 → $30
Oct-14-22Upgrade BofA Securities Underperform → Neutral $27 → $25
Aug-16-22Initiated Piper Sandler Neutral $26
Apr-22-22Resumed Goldman Buy $35
Apr-20-22Initiated Goldman Buy $35
May-25-24 12:00PM
May-21-24 08:48AM
May-15-24 12:14PM
May-14-24 07:00AM
May-02-24 11:39AM
11:15AM Loading…
11:15AM
07:00AM
May-01-24 11:54AM
11:07AM
09:36AM
09:30AM
08:30AM
07:26AM
07:00AM
Apr-30-24 08:00AM
07:00AM Loading…
Apr-24-24 07:00AM
Apr-22-24 02:14PM
Apr-17-24 04:00PM
10:01AM
Apr-11-24 10:15AM
10:00AM
Apr-10-24 09:45AM
Apr-09-24 12:38PM
07:00AM
Apr-08-24 07:00AM
Apr-02-24 12:10PM
Mar-18-24 07:01PM
Mar-15-24 06:15PM
Mar-13-24 12:45PM
Mar-12-24 09:50AM
10:00AM Loading…
Mar-10-24 10:00AM
Mar-08-24 09:45AM
Mar-07-24 06:15PM
07:00AM
Feb-29-24 06:15PM
Feb-23-24 09:50AM
Feb-21-24 09:45AM
Feb-16-24 10:18AM
Feb-15-24 02:40PM
01:34PM
09:30AM
07:37AM
07:30AM
07:00AM
Feb-12-24 09:16AM
Feb-08-24 04:10PM
04:00PM
10:00AM
Feb-07-24 06:15PM
Feb-02-24 02:15AM
Feb-01-24 06:15PM
05:00PM
Jan-30-24 12:10PM
Jan-26-24 06:15PM
Jan-15-24 04:51PM
Jan-12-24 06:15PM
Jan-03-24 04:00PM
07:00AM
Dec-27-23 11:45AM
Dec-22-23 06:15PM
Dec-20-23 02:15PM
12:15PM
Dec-18-23 01:45PM
Dec-14-23 10:45AM
06:05AM
Dec-13-23 04:08AM
Dec-11-23 02:30PM
Dec-01-23 06:16PM
Nov-29-23 03:15PM
Nov-24-23 11:31AM
Nov-21-23 04:00PM
11:45AM
Nov-20-23 01:45PM
Nov-16-23 10:30AM
Nov-15-23 08:57AM
07:15AM
07:00AM
Nov-14-23 01:45PM
10:33AM
05:50AM
Nov-13-23 09:50PM
12:45PM
Nov-10-23 03:00PM
Nov-09-23 11:12AM
Nov-08-23 11:30AM
Nov-07-23 04:00PM
Nov-04-23 12:16PM
Oct-31-23 05:08PM
01:30PM
Oct-26-23 12:00PM
10:37AM
Oct-25-23 12:38PM
09:30AM
07:23AM
07:00AM
Oct-24-23 09:51AM
Oct-23-23 04:00PM
02:00PM
08:00AM
Oct-19-23 10:01AM
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nichols Christian ToddSVP, Chief Commercial OfficerMar 18 '24Sale28.1010,417292,74065,911Mar 18 04:02 PM
Parisi Samuel JosephVP, Finance (Interim PAO)Feb 27 '24Sale29.652,55975,8747,717Feb 27 04:09 PM
LAURENCIN CATO TDirectorFeb 15 '24Option Exercise22.522,69060,57917,859Feb 16 04:01 PM
LAURENCIN CATO TDirectorFeb 15 '24Sale31.852,69085,67615,169Feb 16 04:01 PM
LAURENCIN CATO TDirectorJun 08 '23Option Exercise22.972,63860,59510,117Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 08 '23Sale31.852,63884,0207,479Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 07 '23Option Exercise22.972,80064,31610,279Jun 07 05:12 PM
LAURENCIN CATO TDirectorJun 07 '23Sale31.502,80088,2007,479Jun 07 05:12 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30 '23Option Exercise20.4319,634401,12368,118May 30 08:16 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30 '23Sale28.9327,134784,86240,984May 30 08:16 PM